Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin

This article was originally published in The Pink Sheet Daily

Executive Summary

Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.
Advertisement

Related Content

Genentech Says Lucentis DME Product Will Ship Shortly
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review
CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review
How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

Topics

Advertisement
UsernamePublicRestriction

Register

PS072437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel